点阵激光联合巨大戟醇甲基丁烯酸酯治疗基底细胞癌的探索性研究:OCT与RCM监测
该探索性研究纳入20例组织学证实的浅表型(7例)和结节型(13例)低危基底细胞癌患者,采用点阵CO2激光联合巨大戟醇甲基丁烯酸酯(IM)治疗,必要时第29天重复。第90天组织学治愈率为70%,临床和OCT/RCM治愈率分别为65%和60%,评估方法间一致性高(kappa≥0.796,P<0.0001)。治疗耐受性可接受,但多数清除患者出现瘢痕。
要点
- 点阵CO2激光联合IM治疗低危BCC第90天组织学治愈率70%。
- OCT和RCM可在短期随访中检测亚临床BCC(25%病例)。
- 浅表型与结节型BCC清除率相似(P=0.354),两种IM浓度疗效无差异(P=0.141)。
核心结论
- 两次点阵激光联合IM治疗低危BCC显示潜在疗效且耐受性可接受。
- OCT和RCM在短期随访中有望检测亚临床BCC。
研究设计与样本
- 探索性研究,纳入20例组织学证实的浅表型(n=7)和结节型(n=13)低危BCC患者。
- 第29天和第90天进行临床、OCT和RCM评估,第90天进行组织学评估;若BCC持续则第29天重复治疗。
主要发现
- 第29天,18/20例患者因临床、OCT或RCM检测到残留BCC而接受第二次治疗。
- OCT和RCM在5/20例(25%)中检测到亚临床BCC。
- 第90天组织学总治愈率为70%,临床治愈率65%,OCT/RCM治愈率60%,评估方法间一致性高(kappa≥0.796,P<0.0001)。
- 浅表型与结节型BCC清除率相似(P=0.354),IM 0.015%与0.05%治疗病灶清除率相似(P=0.141)。
- 局部皮肤反应可耐受,但多数清除患者观察到瘢痕。
临床怎么用
- 对于低危BCC,点阵激光联合IM可作为潜在治疗选择,需注意瘢痕风险。
- OCT和RCM可用于短期随访监测亚临床BCC。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Basal cell carcinomas (BCCs) have previously been treated off-label with ingenol mebutate (IM). Ablative fractional laser (AFL) may improve efficacy of IM by increasing drug uptake in the tumour. Optical coherence tomography (OCT) and reflectance confocal microscopy (RCM) detect BCC non-invasively. Our aim was to investigate BCC response and tolerability after combined AFL and IM treatment of low-risk BCCs. METHODS: Twenty patients with histologically verified superficial (n = 7) and nodular (n = 13) BCCs were treated with combined fractional CO2 -laser (10 600 nm) and IM 0.015% or 0.05%, the concentration depending on anatomical location. BCC response was evaluated clinically, by OCT and RCM at day 29 and 90 after first treatment, and histologically at day 90. Treatment was repeated at day 29 if BCC persisted. Local skin reactions (LSRs) were assessed using LSR scale at all visits. RESULTS: At day 29, 18/20 patients received a second treatment due to residual BCC detected clinically, by OCT or RCM. OCT and RCM presented subclinical BCCs in five of 20 cases (25%). At day 90, overall histological cure rate was 70%, corresponding to clinical (65%) and OCT/RCM (60%) cure rates, and agreement between evaluation methods was substantial (kappa ≥ 0.796, P < 0.0001). Clearance rates were similar for sBCCs and nBCCs (P = 0.354) and for lesions treated with IM 0.015% and 0.05% (P = 0.141). LSRs were tolerable, but scarring was observed in the majority of cleared patients. CONCLUSION: Two treatments of combined AFL and IM show potential to treat low-risk BCCs with acceptable tolerability. OCT and RCM show promise to detect subclinical BCCs at short-term follow-up.
引用
- Banzhaf CA, Phothong W, Suku MH, et al. Basal cell carcinoma treated with combined ablative fractional laser and ingenol mebutate - an exploratory study monitored by optical coherence tomography and reflectance confocal microscopy. J Eur Acad Dermatol Venereol. 2019. PMID: 31442334. doi:10.1111/jdv.15907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。